Ihc.L

IHC.L's capital structure is characterized by a debt-to-equity ratio of 0.9, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 2.13, suggesting it can cover short-term obligations but with limited excess capacity. Free cash flow is negative at -14.7 million GBP, and operating cash flow is also negative at -1.5 million GBP, signaling cash flow constraints that may pressure liquidity in the near term.

Profitability metrics are weak, with a return on equity of -89.97% and a return on assets of -36.43%, both significantly below industry norms. The company reported a net loss of 14.97 million GBP and an operating loss of 14.69 million GBP, indicating a challenging operating environment. Gross profit of 16.38 million GBP on 382.51 million GBP in revenue yields a gross margin of 4.28%, which is likely below the industry median for medical equipment and distribution firms.

Geographic and segment exposure is not explicitly detailed in the available data, but the company's revenue concentration is inferred to be within the UK and Europe, given its GBP-based financials and the absence of disclosed international operations. No material revenue diversification across segments is reported, which could increase exposure to regional or sector-specific risks.

Growth trajectory is uncertain, with no disclosed revenue growth or decline in the most recent period. The company's operating losses and negative cash flows suggest a lack of momentum, and no clear catalysts for improvement are identified in the available data. Analysts have assigned a mean price target of 57.50 GBP, with a wide range from 33.00 GBP to 82.00 GBP, reflecting divergent views on the company's future performance.

Risk factors include liquidity constraints, as the company has negative net cash after subtracting total debt. The risk of dilution is assessed as low, with no recent or disclosed share issuance activity. However, the company's negative operating cash flow and free cash flow could necessitate future financing, potentially leading to dilution if equity is used to fund operations.

Recent events include the publication of the latest financial results, which show continued operating losses and cash flow challenges. No material events such as mergers, acquisitions, or regulatory changes are disclosed in the available data. Analysts have issued a mean recommendation of 1.00, indicating a strong buy consensus, but this is based on limited data and may not reflect the company's underlying fundamentals.